Amyotrophic Lateral Sclerosis market to grow due to rising disease prevalence, with promising therapies like Masitinib & PrimeC.
The market for amyotrophic lateral sclerosis is projected to expand due to the rising prevalence of the disease. This growth is bolstered by the development of new pipeline therapies, including Masitinib from AB Sciences, PrimeC from Neurosense Therapeutics, RNS60 from Revalesio, IFB-088 from InFlectis BioScience, and NP001. These advancements are anticipated to drive growth in the market for ALS treatment in the upcoming years.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments